Clinical Trials
30 trialsNCT01924819 2025-03-04
TOPGEAR
Australasian Gastro-Intestinal Trials Group
Phase 2/3 Active not recruiting
NCT00486356 2024-01-03
Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer
University of Nebraska
Phase 1 Completed
NCT02338518 2023-09-29
SVOSA
Jinling Hospital, China
Phase 3 Unknown
NCT02395640 2021-10-26
The Comparison of XELOX and EOX in the First-line Treatment of Advanced Gastric Cancer
Fudan University
Phase 3 Completed
NCT02128243 2021-03-26
MATEO
AIO-Studien-gGmbH
Phase 2 Completed
NCT00052910 2020-05-07
Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT02076594 2019-10-09
Low-Tox Vs Eox In Patients With Locally Advanced Unresectable Or Metastatic Gastric Cancer
Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
Phase 3 Terminated
NCT01216644 2019-06-19
5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer
Krankenhaus Nordwest
Phase 2/3 Completed
NCT00601705 2019-04-30
Epirubicin, Oxaliplatin and Fluorouracil (EOF) in Cancer of the Esophagus, Gastroesophageal Junction, or Stomach
Case Comprehensive Cancer Center
Phase 2 Completed
NCT02177552 2019-02-15
SEED
Rigshospitalet, Denmark
Phase 2 Unknown
NCT00215644 2018-11-02
MATRIX EG
Merck KGaA, Darmstadt, Germany
Phase 2 Completed
NCT02358863 2018-09-06
mEGA
Georgetown University
Phase NA Terminated
NCT01830270 2018-07-26
IPEC-GC
Centre Hospitalier Universitaire de Besancon
Phase 2 Terminated
NCT01234324 2018-01-23
NEOPECX
AIO-Studien-gGmbH
Phase 2 Completed
NCT02949258 2016-10-31
NCT-B4
Jinling Hospital, China
Phase 2 Unknown
NCT01123473 2016-10-12
Epirubicin Hydrochloride, Cisplatin, and Fluorouracil or Capecitabine With or Without Lapatinib Ditosylate as First-Line Therapy in Treating Patients With Stomach Cancer or Gastroesophageal Junction Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Terminated
NCT00454636 2016-09-29
A Study of Xeloda (Capecitabine) in Combination With Chemotherapy in Patients With Advanced and/or Metastatic Gastric Cancer.
Hoffmann-La Roche
Phase 2 Completed
NCT00130936 2016-02-15
Study of Epirubicin (Pharmorubicin®), Carboplatin (Paraplatin®) and Capecitabine (Xeloda®) (ECC) in the Treatment of Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer With Pharmacogenetic Correlates
AHS Cancer Control Alberta
Phase 1/2 Terminated
NCT01697072 2016-02-09
RILOMET-1
Amgen
Phase 3 Terminated
NCT00737438 2016-02-03
Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00718354 2015-05-13
GASTRANOX
Thrombosis Research Institute
Phase 3 Completed
NCT00215514 2014-07-29
Adjuvant Chemoradiation Therapy for Gastric or Gastroesophageal Junction Adenocarcinoma
Dana-Farber Cancer Institute
Phase EARLY_PHASE1 Completed
NCT00375999 2014-03-03
Docetaxel and Epirubicin in Advanced Gastric Cancer
Yonsei University
Phase 2 Completed
NCT00002615 2013-12-19
Surgery With or Without Combination Chemotherapy in Treating Patients With Stomach Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00719550 2013-12-05
AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer
Amgen
Phase 1/2 Completed
NCT01964027 2013-10-17
SIEG
Anhui Medical University
Phase 2 Unknown
NCT00123318 2013-06-18
A Feasibility Study to Evaluate Adjuvant Chemoradiotherapy for Gastric Cancer
Trans Tasman Radiation Oncology Group
Phase 3 Completed
NCT00004873 2012-05-15
Combination Chemotherapy in Treating Patients With Advanced Stomach Cancer
Swiss Cancer Institute
Phase 2 Completed
NCT00021047 2012-03-08
Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT00075465 2008-07-24
Docetaxel and Epirubicin as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Adenocarcinoma of the Stomach
National Cancer Institute (NCI)
Phase 2 Unknown